This roundtable series evaluates the use of combination therapies using immunotherapy and chemotherapy in patients with advanced Hodgkin lymphoma, as discussed by key opinion leaders and participants at virtual live events.
Considerations for Frontline Treatment of Advanced Hodgkin LymphomaMarch 29th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the history of the use of brentuximab vedotin in Hodgkin lymphoma and how to evaluate patients after primary therapy.
Tolerability With Brentuximab Vedotin Treatment in Hodgkin LymphomaMay 24th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.